URGN Overview

Company Profile

Related stocks

SEPN • United States

Septerna, Inc.

38.37 USD

1.79B USD 1Y +64.1%

GENB • United States

Generate Biomedicines, Inc.

14.34 USD

1.84B USD

NUVB • United States

Nuvation Bio Inc.

5 USD

1.76B USD 1Y +33.1%

PVLA • United States

Palvella Therapeutics, Inc.

138.77 USD

2B USD 1Y +75.5%

VIR • United States

Vir Biotechnology, Inc.

11.7 USD

1.98B USD 1Y +83.8%

MAZE • United States

Maze Therapeutics, Inc.

27.11 USD

1.51B USD 1Y -9.5%

KLRA • United States

Kailera Therapeutics, Inc.

11.61 USD

1.51B USD

COAG • United States

Hemab Therapeutics Holdings, In

31.62 USD

1.48B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

4 Metrics

Country

Region

Sector

Industry

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

91.8% p.a.

Max Drawdown (5Y)

-82.6%

Sharpe Ratio (5Y)

0.17

Beta Factor

1.58

Size Class

Small Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

High market risk: Beta of 1.58 indicates above-average volatility compared to the broader market.

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (91.8% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -94.0% in the extended horizon.